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Abstract: Large randomized clinical trials and prior meta-analyses indicate that second-generation
BCR-ABL tyrosine kinase inhibitors (TKIs) improve surrogate biomarkers in patients with chronic
myeloid leukemia (CML) without providing survival benefits. The objective is to evaluate the
long-term efficacy and the occurrence of vascular occlusion with second-generation BCR-ABL TKIs
compared with imatinib in patients with CML. Three scientific databases, a clinical registry and
abstracts from congress were searched to identify all randomized controlled trials that compared a
second-generation BCR-ABL TKI to imatinib in patients with CML. Outcomes extracted were overall
survival, major molecular response and complete cytogenetic response, arterial occlusive events and
venous thromboembolism. These data were synthesized by odds ratios using a fixed-effect model.
This meta-analysis included 4659 participants from 14 trials. Second-generation BCR-ABL TKIs did
not improve overall survival compared with imatinib, even at longer follow-up (OR, 1.17 (95% CI,
0.91–1.52)). They improved surrogate biomarkers at 12 and 24 months but increased the risk of arterial
occlusion (ORPETO, 2.81 (95% CI, 2.11–3.73)). The long-term benefits of second-generation TKIs are
restricted to surrogate outcomes and do not translate into prolonged survival compared to imatinib.
Given the long-term use, frontline therapy should be chosen carefully, with special attention to the
patients’ quality of life and cardiovascular risks.
Keywords: protein kinase inhibitors; overall survival; meta-analysis; leukemia; myelogenous chronic;
BCR-ABL positive; arterial occlusive disease
1. Introduction
1.1. Rationale
Treatment of chronic myeloid leukemia (CML) has significantly changed over the last two decades
with the development of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL. Today, five BCR-ABL
TKIs are approved to treat CML (a sixth BCR-ABL TKI, radotinib, is approved in Korea only). Four of
Cancers 2020, 12, 1242; doi:10.3390/cancers12051242 www.mdpi.com/journal/cancers
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them are indicated for use in newly diagnosed chronic-phase (CP) CML patients [1]. The optimal choice
is challenging for physicians. The first-generation TKI, imatinib is a well-known safe and effective
drug, whereas second-generation TKIs (i.e., dasatinib, nilotinib or bosutinib) provide faster molecular
responses but are considered less safe than imatinib [2,3]. Evidence-based guidelines recommend
basing the decision of the frontline therapy on the treatment aim, the treatment cost and the TKI safety
profiles [1,4,5]. The use of a second-generation TKI over imatinib is particularly recommended for
patients with moderate- or high-risk Sokal scores. Second-generation TKIs are also recommended for
young patients because of the higher probability of treatment-free remission with these TKIs [1].
Despite their benefit in molecular and cytogenetic responses, second-generation TKIs have not
demonstrated survival benefits over imatinib in clinical trials [6,7], possibly because of the short
follow-up. Meta-analyses have been performed to compare the efficacy of second-generation BCR-ABL
TKIs with imatinib in patients with CML [8–12]. All concluded that second-generation TKIs provide
better surrogate outcomes (i.e., molecular and cytogenetic responses) but no survival benefit [8,10].
However, overall survival analyses were restricted to data at one year and showed high rate of survival.
This limits the probability of demonstrating a significant benefit of second-generation TKIs in terms of
survival [8]. Since then, additional data from randomized clinical trials (RCTs) with longer follow-up
have been published [6,7,13]. The 5-year report of the ENESTnd trial, a large phase 3 trial, revealed
that nilotinib induces survival benefits compared with imatinib [14]. In regard to safety, a prior
meta-analysis assessed the risk of vascular occlusion of second-generation BCR-ABL TKIs plus the
third-generation TKI ponatinib because of a signal during ponatinib development that led to the
subsequent discontinuation of the phase 3 trial [15,16]. That study concluded that a greater risk of
arterial occlusion was observed compared to the risk with imatinib [17]. Subgroup analyses indicate
that an increased risk exists with two of the three second-generation TKIs (dasatinib and nilotinib).
The lack of data did not allow firm conclusions about bosutinib, recently approved as a first-line drug
for CP-CML [17–19]. Since then, the results from an additional phase 3 study have been published
on bosutinib. The inclusion of data on long-term follow-up permits a more global approach of the
benefit-risk profile of second-generation BCR-ABL TKIs.
1.2. Objectives
The study proposed is the first meta-analysis aimed at assessing the long-term overall survival,
major molecular response (MMR) and cytogenetic response (CCyR) of second-generation BCR-ABL
TKIs compared with imatinib in patients with CML in RCTs. This meta-analysis also compares the
occurrence of arterial and venous occlusion with first-line BCR-ABL TKIs in CML patients.
2. Results
2.1. Eligible Studies and Study Characteristics
The literature search yielded 918 records. After title and abstract screening, 113 full texts were
considered for further investigation. The full-text screening excluded 93 articles. Major exclusion
reasons were the lack of pertinent data, outdated data or an inappropriate study design. Finally,
we identified 14 clinical trials reported in 20 abstracts and articles that met the inclusion criteria,
involving a total of 4659 participants [6,7,13,20–38]. Figure 1 shows the flow of studies in the systematic
review process and Table S1 lists the key characteristics of the 14 studies. All included studies are RCTs.
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(95% CI: 0.91–1.52); Figure 2). This result was consistent between TKIs (subgroup difference, I² = 0%; 
Figure 2) and between nilotinib dose regimens (300 mg BID: OR, 1.21 (95% CI: 0.66 to 2.24); 400 mg 
BID: OR, 1.53 (95% CI: 0.86–2.74); Figure S2). The anticipated absolute effect of overall survival was 
0.9% superior (95% CI: −0.6–2.1) with second-generation TKIs over imatinib (survival rate of 93.7%, 
Table 1). The omission of clinical trials performed in previously treated CML patients did not 
significantly change the results (OR, 1.20 (95% CI: 0.92 to 1.57); Figure S3). Only two studies reported 
Figure 1. PRISMA flow diagram of the study selection process. Abbreviations: AOE: arterial occlusive
event; CCyR: complete cytogenetic response; MMR: major molecular response; OS: overall survival;
TKI: tyrosine kinase inhibitor; VTE: venous thromboembolism.
The risk of bias for each of the 14 included studies is shown in Figure S1.
2.2. Overall Survival
Of the 14 included studies, 12 reported overall survival data. There was no significant difference
between second-generation TKIs and imatinib in the outcome of overall survival (OR, 1.17 (95%
CI: 0.91–1.52); Figure 2). This result was consistent between TKIs (subgroup difference, I2 = 0%;
Figure 2) and between nilotinib dose regimens (300 mg BID: OR, 1.21 (95% CI: 0.66 to 2.24); 400 mg
BID: OR, 1.53 (95% CI: 0.86–2.74); Figure S2). The anticipated absolute effect of overall survival
was 0.9% superior (95% CI: −0.6–2.1) with second-generation TKIs over imatinib (survival rate of
93.7%, Table 1). The omission of clinical trials performed in previously treated CML patients did
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not significantly change the results (OR, 1.20 (95% CI: 0.92 to 1.57); Figure S3). Only two studies
reported overall survival in clinical trials comparing high-dose imatinib to second-generation TKIs.
Their analysis demonstrated no survival benefit of high-dose imatinib compared to second-generation
TKIs (Figure S3 and Table S2).
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The MMR rate at 12 and 24 months and the CCyR rate at 12 months were reported in 12, 6 and
9 studies respectively. Of these three efficacy outcomes, all favored second-generation TKIs (MMR
12 months: OR, 2.01 (95% CI: 1.77–2.30); MMR 24 months: OR, 1.40 (95% CI: 1.17–1.67)); CCyR
12 months: OR, 1.50 (95% CI: 1.31–1.72); Figure S4), even compared with high-dose imatinib (Figure S3).
These results were consistent between studies for MMR at 12 and 24 months (respectively, I2 = 20%
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and 0%), but the I2 statistic indicated moderate heterogeneity for CCyR at 12 months (I2 = 48%).
This inconsistency was mainly due to the heterogeneity between nilotinib (I2 = 81%) and bosutinib
trials (I2 = 64%). Differences between these study designs were related to TKI dose and population
(i.e., patients previously treated vs. treatment-naïve patients; Table S1). The stratification by nilotinib
dose regimen demonstrated similar results between 300 and 400 mg BID (Figure S2), and the omission
of clinical trials performed in previously treated CML patients did not significantly change the results
(Figure S3).
2.4. Vascular Occlusion
The risk of AOEs was increased with second-generation TKIs compared with imatinib (ORPETO,
2.81 (95% CI: 2.11–3.73); Figure 3) and high-dose imatinib (Figure S3). With imatinib, 23 out of 1000
patients developed an arterial occlusion, whereas this meta-analysis estimated that this rate increased to
61 out of 1000 patients with second-generation TKIs (95% CI: 46–79, Table 2). There was a trend toward
an increased risk of venous thromboembolism (VTE) (ORPETO, 1.74 (95% CI: 0.82–3.66); Figure S4).
The risk of AOEs was consistently higher for second-generation TKIs and the difference was
significant for nilotinib (OR, 3.89 (95% CI: 2.47–6.11)) and dasatinib (OR, 2.68 (95% CI: 1.72–4.17)).
Only bosutinib was not associated with a significantly increased risk of AOEs compared with imatinib
(OR, 1.61 (95% CI: 0.85–3.07)). However, this result became significant when simulating recruitment
similar to that with dasatinib and nilotinib (i.e., repeating the analysis until the same number of
patients was obtained). Arterial occlusive events (AOEs) occurred more frequently with nilotinib 400
mg BID than with nilotinib 300 mg BID (300 mg BID: 3.32 (95% CI: 1.56–7.09); 400 mg BID: 5.19 (95%
CI: 3.14–8.57); Figure S2).
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Table 2. Arterial occlusive events in patients with CML receiving second-generation BCR-ABL TKIs.
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2.5. Risk of Bias
The analysis of the risk of bias is reported in the Figure S1. Four studies of the 12 included in
the AOE analysis were considered to have high concern. Indeed, because of the discovery of the
risk of vascular occlusion with another BCR-ABL TKI (i.e., ponatinib) before these four studies were
conducted, the reporting and the subjectivity of similar events (e.g., chest pain, phlebitis) with the
investigated treatments might have been affected. All of the 14 included trials were at moderate risk of
bias because of the high rate of treatment discontinuation or switching and the possibility of modifying
the treatment dose. Additional risks of potential bias were the lack of details of the randomization
process, the selection of the reported outcome and the open-label design. Funnel plots and Egger’s
tests indicated no evidence of publication bias (Figure S5).
3. Discussion
3.1. Should Second-Generation TKIs Be Favored over Imatinib for Treatment-Naïve CP-CML Patients?
3.1.1. Are Second-Generation TKIs More Efficient Than Imatinib to Treat CP-CML?
This is the first meta-analysis of second-generation BCR-ABL TKIs that provides long-term
estimates on efficacy and safety compared to imatinib. The major finding of this meta-analysis of 14 RCTs
including 4659 CML patients was that second-generation BCR-ABL TKIs did not significantly improve
short- or long-term overall survival compared with imatinib. Except for nilotinib, for which survival
superiority was suggested in the ENESTnd trial [14], this absence of the benefit of second-generation
TKI in terms of survival is in accordance with the RCT results [6,7]. Unsurprisingly, and in line with
large clinical trials, surrogate outcomes such as the rates of MMR and CCyR at 12 and 24 months were
improved with second-generation BCR-ABL TKIs compared to imatinib.
Based on the higher rate of surrogate outcomes with second-generation TKIs, numerous recent
studies have concluded that second-generation TKIs are superior for frontline treatment of CML,
challenging the position of imatinib [2,9,10,12]. Surrogate outcomes have been adopted as predictive
of overall survival at the time CML patients were treated with interferon-α because of the strong
correlation between cytogenetic response and survival. They have then been used for TKI marketing
authorization because patient-relevant outcomes (e.g., overall survival and progression-free survival)
are time dependent. However, BCR-ABL TKIs and interferon-α differ in their mechanisms of action,
but the validity of the surrogate outcomes to predict patient survival with TKIs has not been questioned.
Different molecular responses (early molecular response and MR 4.5) have been proposed as surrogate
markers for overall survival but have failed to predict patient survival [39]. To our knowledge, it has
not been demonstrated that a potential TKI effect on survival is explained by molecular response.
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These biomarkers may not fully capture the action TKIs have on the overall survival. Indeed, the lack
of selectivity of BCR-ABL TKIs is responsible for numerous adverse events that may affect patient
survival (e.g., ischemic stroke or myocardial infarction) [40]. A long-term study of patients with
CML treated by second- or third- generation TKIs demonstrates that approximately a third of death
were related to cardiovascular diseases [41]. This potentially explains why, even with long follow-up,
improvement in surrogate outcomes with second-generation TKIs does not result in better overall
survival. Consequently, surrogate outcomes should not be interpreted alone. The long-term benefits,
treatment safety and patients’ quality of life (QoL) should be preferred and seem more relevant because
of the long life expectancy of CP-CML patients, close to that of the general population [42].
3.1.2. Do All Second-Generation TKIs Favor Arterial Occlusion?
As imatinib and second-generation TKIs confer similar survival probability, their vascular safety
is important to consider avoiding premature non-CML-related deaths or vascular-related disabilities.
Our meta-analysis confirms that the risk of AOEs is higher with second-generation TKIs than with
imatinib. Of 1000 CP-CML patients, 38 more patients (95% CI, 24–57) will develop an arterial occlusive
disease with second-generation TKIs compared with imatinib. In accordance with real-life studies,
the risk of arterial occlusion has reportedly been higher with nilotinib, dasatinib and ponatinib.
Bosutinib has the safer vascular profile and is currently not associated with a significant increase of the
risk of vascular occlusion [43,44]. However, the size of the population of the bosutinib analysis is limited
compared to the number of patients in the dasatinib and nilotinib subgroups. This lack of statistical
evidence should therefore not be seen as evidence of an absence of a true risk. Further investigations
are needed to improve the power of the analysis. In addition, data with bosutinib were obtained from
two trials sponsored by the marketing authorization holder. Assessment of the AOE analysis indicated
that higher ORs were reported in institutional or academic trials (i.e., NCT00070499 and NordCML006)
than in sponsored industrial studies, raising some concerns about the risk of bias.
3.1.3. Imatinib and Second-Generation TKIs Have Limited Impact on Patients’ QoL
The potential long-term duration of BCR-ABL TKI treatment led patients and physicians to pay
more attention to treatment long-term risks and the impact on patients’ QoL. However, the latter has
rarely been studied in clinical trials. The few such studies report similar QoL with imatinib as in the
general population among older patients (older than 59 years) [45]. However, younger patients are
more affected and report limitations in work and daily activities compared to the age-matched general
population (i.e., without cancer) [45]. With second-generation TKIs, quality-of-life sub analyses have
been performed in four large RCTs (i.e., BFORE, ENESTnd, ENESTchina and SPIRIT2) [46–51]. All these
analyses reported no differences in QoL between the second-generation TKIs and imatinib [46–51].
3.1.4. Recommendations for Frontline Treatment of CP-CML
Imatinib and second-generation BCR-ABL TKIs are all highly effective in treating CP-CML and
provide survival close to that of the age-matched population. Imatinib has demonstrated reassuring
long-term safety and efficacy [52]. At 10 years, the overall survival rate was estimated to be 83.3%,
and fewer than 10% of patients developed serious adverse events [52]. Second-generation TKIs increase
the rate of molecular and cytogenetic responses but do not provide benefits in patient survival or QoL
compared with imatinib.
The induction of faster and deeper molecular responses with second-generation TKIs compared
to imatinib in treatment-naïve patients has generated interest over the last few years for these drugs
because of the increasing number of candidates for TKI discontinuation (i.e., a higher number of patients
who achieved rapid molecular remission) [53]. However, in retrospect, treatment discontinuation
was less successful than announced, with a higher number of patients relapsing after TKI cessation
than expected. Recent studies indicate that TKI discontinuation was successful in 20% of patients (i.e.,
almost 40% of CML patients are eligible for treatment discontinuation, with a success rate of 50%),
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and criteria for trying treatment cessation are more constraining [54]. In addition, patients should be
treated longer (i.e., optimally more than 8 years) with a TKI before trying treatment cessation [54].
Due to the safety profile of second-generation TKIs, particularly the vascular issue damage from
these treatments (with the exception of bosutinib, which requires further investigation), the frontline
treatment choice should not focus solely on the objective of treatment-free remission. Arterial occlusion
occurred more frequently in patients with prior cardiovascular risk factors. Therefore, an estimation
of 10-year arteriosclerotic cardiovascular disease risk, as recommended by the ACC/AHA, should be
applied to CML patients before making a treatment decision [55].
The treatment choice should then be made individually by carefully weighing the benefits and
the risks of each TKI. These results support the current NCCN guidelines, particularly to limit the
use of second-generation TKIs as frontline drugs for young patients. Finally, the treatment cost
should be taken into account. A recent study demonstrates that the one-year health care expenditures
were significantly higher among patients treated with second-generation BCR-ABL TKIs as first-line,
compared with those treated with imatinib [56].
3.1.5. Is the BCR-ABL TKI Dose Optimal?
Modification of the TKI dose regimen has already been proposed as a potential measure to minimize
the risk of AOEs, but data were insufficient to provide formal recommendations [8]. The results of
our meta-analysis suggest that the efficacy of nilotinib is similar independent of the dose. However,
nilotinib 400 mg BID was associated with a higher incidence of AOEs. Therefore, the use of 400 mg BID
nilotinib is questionable. Dasatinib has been tested in a RCT only at 100 mg QD in newly diagnosed
CP-CML patients. Future studies should assess the benefits of reduced doses of nilotinib and dasatinib
to minimize the risk of arterial occlusion while preserving efficacy. For bosutinib, the comparison
between the BELA and the BFORE trial, in which participants were treated with 500 mg and 400 mg
QD, respectively, indicates a similar OR for efficacy outcomes and AOE occurrence. A dose reduction
to 300 mg QD allowed a reduction of adverse events and better tolerability. However, its effect on
efficacy and arterial occlusion has not been studied [57].
3.2. Measures to Minimize the Vascular Risk with Second-Generation TKIs
Several measures have already been recommended in the literature to minimize the risk of
arterial occlusion [17,58]. These recommendations aim to minimize cardiovascular risk by acting on
common cardiovascular risk factors. Prevention treatment is only recommended for patients with
diagnosed cardiovascular disease or diabetes. In the European Summary of Product Characteristics
(EU-SMPC), recommendations to prevent arterial occlusion are only provided for nilotinib [59–61].
The SMPC of nilotinib does not suggest additional measures that evaluate cardiovascular risk or
the management or monitoring of common cardiovascular risk factors. Recent in vitro and in vivo
studies suggest that nilotinib and ponatinib may induce arterial occlusion through coronary artery
vasospasm by inhibiting the RAS/RAF/MEK pathway and increasing Ca2+ release by activating the
calcium channel [62,63]. The use of diltiazem, a calcium channel blocker, to prevent vascular occlusion
is an interesting possibility that should be further investigated in clinical settings with nilotinib and
ponatinib [63].
3.3. Strengths and Limitations
A major limitation of this meta-analysis is the use of aggregate data from the studies because of
the lack of access to individual data. This precludes additional calculations such as overall survival
analyses based on patients’ Sokal score and age and the integration of patients’ comorbidities in the
analysis of AOEs. In addition, access to individual data would provide the advantage that statistical
analyses could be standardized between but also within studies, and allow the computation of the
number of patients eligible for treatment discontinuation. Progression-free survival was not analyzed
in our meta-analysis as its definition differs between studies [64]. Another limitation was the selection
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of the ITT population as data source, as this population does not take into account the proportion of
patients who switched to another TKI.
A major strength of this meta-analysis is the integration of both published and unpublished data
that limit the risk of publication bias. As much as possible, we confront the data from the different
sources and use a conservative approach to select the data that have been included in the quantitative
analysis. Another strength of our analysis is that we assessed the rates of molecular and cytogenetic
responses at specific time points (e.g., MMR at 12 months). Most clinical trials have investigated these
surrogate outcomes over a period of time, also called the cumulative response, and the reporting of
these data is often unclear (i.e., no specification of the type of analysis). Due to the rapid variation
of the molecular response, the cumulative incidence is frequently higher than the response rate at
a specific time point. Loss of molecular or cytogenetic responses can be the consequence of lack of
compliance, treatment intolerance and drug resistance, three factors that are revealed by the analysis of
responses at specific time points rather than cumulative response.
4. Materials and Methods
4.1. Search Methods
This meta-analysis was performed in accordance with the protocol for meta-analyses published in
2015 [8] and complied with the PROSPERO protocol 2014:CRD42014014147. Three scientific databases
(PubMed (from 1966), Scopus (from 1995) and CENTRAL (Cochrane Central Register of Controlled
Trials; from 1996)), a clinical trial registry (clinicaltrials.gov) and abstracts from the last 3 years of
3 meetings (i.e., ASCO, ESMO and ASH congresses) were searched up to 14 January 2019 using the
search strategy reported in Method S1. Only English publications were considered. This meta-analysis
follows the PRISMA statement (Table S3).
4.2. Data Collection
4.2.1. Study Selection
Two researchers (HH and JD) independently screened all titles and abstracts identified from
the literature search to determine potentially eligible studies. We included RCTs that compared a
second-generation TKI approved for first-line CML treatment with imatinib in patients with CML.
The full texts of these potentially relevant articles were then assessed independently by the same
researchers (HH and JD) based on predefined inclusion and exclusion criteria. Disagreements were
resolved through discussion with a third author (JMD).
4.2.2. Data Extraction
The data extraction was performed for each study independently by 2 researchers (HH and
JD) using a standard data extraction form. The outcomes extracted were overall survival, MMR
and CCyR at predefined time points (12 months, 24 months, 36 months, 48 months and 60 months,
when available), as well as AOEs and VTEs. Method S2 presents the list of terms considered as AOEs
and VTEs. Reviewers took special care to extract responses at a specific time point rather than the
cumulative response (i.e., rate of response achieved by the time point, regardless of whether they lost
the response/discontinued or not). The number of patients alive was also preferred over the estimated
overall survival (Kaplan–Meier analysis), and the overall survival with the longest study follow-up
was included.
When discrepancies occurred between sources a conservative approach was adopted. For AOE
and VTE analyses, data were extracted from the adverse event report rather than from secondary
analyses performed by the study sponsor (i.e., vascular safety analyses performed as secondary
outcomes) when possible, to limit the risk of bias.
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4.3. Data Analysis
4.3.1. Data Synthesis
We conducted meta-analyses of dichotomous variables with the fixed-effect model (FEM) by
computing odds ratios (ORs) and 95% confidence intervals (CIs). For the AOE and VTE analyses, ORs
were computed using the Peto method because the rate of events was low [65]. Statistical analyses were
performed using Review Manager (RevMan) version 5.3 (Copenhagen, 2014, https://training.cochrane.
org/online-learning/core-software-cochrane-reviews/revman/revman-5-download). In addition to
ORs, anticipated absolute effects were computed using a GRADE profiler (GRADEpro GDT, McMaster
University, 2015). This measure was expressed as a risk difference with its 95% CI and is based on the
baseline risk (i.e., the risk in the comparison group) and the relative effect of the intervention.
4.3.2. Subgroup Analysis and Investigation of Heterogeneity
Stratification per treatment was performed, as well as per TKI dose when data were available.
Heterogeneity among trials was quantified by the I2 statistic, with an I2 value < 25% reflecting mild
heterogeneity, 25%–50% reflecting moderate heterogeneity and > 50% reflecting severe heterogeneity.
4.3.3. Sensitivity Analysis
Sensitivity analyses were performed as a repeat of the meta-analysis by substituting previously
treated patients in order to explore their impact on MMR and CCyR. Sensitivity analyses were also
performed by subtracting trials with high-dose imatinib (i.e., greater than 400 mg per day).
4.3.4. Assessment of Risk of Bias in Included Studies
The risk of bias was assessed using the Cochrane Collaboration’s risk of bias 2 (RoB 2) tool for
RCT [66]. To assess the risk of reporting bias, we carried out an assessment of publication bias using
funnel plots. Funnel plot asymmetry was evaluated using Egger’s regression tests [67].
5. Conclusions
Since the introduction of BCR-ABL TKIs, patients’ and physicians’ concerns have shifted because of
their high efficacy, and more attention has been paid to treatment toxicity and patients’ QoL. Even with
long follow-up, there is no direct evidence of a survival benefit associated with second-generation
BCR-ABL TKIs. Given the long-term use of BCR-ABL TKI treatment, the therapeutic option should
be selected individually and based on multiple factors, including cardiovascular safety and QoL.
Future research should focus on these two last points. To date, the cardiovascular safety of bosutinib is
reassuring. In light of the present results, it is anticipated that an in-depth reanalysis of the clinical
trials by the marketing authorization holders together with the regulatory bodies would be needed to
update the product information with the most recent data analysis. This would provide health care
professionals with updated recommendations on the benefits and risks of these medicines.
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